BBNX Stock Analysis: Buy, Sell, or Hold?
BBNX - Beta Bionics, Inc. Common Stock
$13.67
-0.03 (-0.22%)
▼
5d:
-4.94%
30d:
+28.84%
90d:
+24.05%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When BBNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BBNX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BBNX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BBNX is currently trading at $13.67, which is considered slightly high relative to its 30-day fair value range of $10.98 to $14.26.
Technical Outlook: Technically, BBNX is showing sideways momentum. Immediate support is located at $13.02, while resistance sits at $15.00.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.18 (+40.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BBNX is showing sideways momentum. Immediate support is located at $13.02, while resistance sits at $15.00.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.18 (+40.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$10.98 -
$14.26
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.3% below Wall St target ($19.18)
Trading Range Analysis
30-Day Trading Range
$10.98 -
$14.26
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$1.67
(12.2%)
Support & Resistance Levels
Support Level
$13.02
Resistance Level
$15.00
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.72
Wall Street Target
$19.18
(+40.3%)
Revenue Growth (YoY)
56.6%
Profit Margin
-60.3%
Share & Embed Analysis
Last updated: June 23, 2026 7:56 PM ET
Data refreshes hourly during market hours. Next update: 8:56 PM
Data refreshes hourly during market hours. Next update: 8:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Hopman
SELL
353 shares
2026-03-04
Mark Hopman
SELL
834 shares
2026-03-02
Mike Mensinger
SELL
1064 shares
2026-03-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 60 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 61 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 56 HOLD |
